Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes

  title={Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes},
  author={P. Villaseca and P. Hormaza and I. C{\'a}rdenas and E. Oestreicher and E. Arteaga},
  journal={The European Journal of Contraception & Reproductive Health Care},
  pages={155 - 165}
  • P. Villaseca, P. Hormaza, +2 authors E. Arteaga
  • Published 2004
  • Medicine
  • The European Journal of Contraception & Reproductive Health Care
  • Objective Ethinylestradiol (EE) combined with the antiandrogenic progestin cyproterone acetate (CPA) is a possible treatment in polycystic ovary syndrome (PCOS). We investigated the impact of EE/CPA on lipid and carbohydrate metabolism in women with PCOS,who were otherwise healthy. Method The 31 women were separated into two groups paired by body mass index (BMI): Group A (control, n = 15) were cycled with 10 mg medroxyprogesterone acetate (MPA) x 10 days (Provera®, Pharmacia & Upjohn) every… CONTINUE READING
    21 Citations
    Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome
    • 26
    • Highly Influenced
    Different Effects of Myoinositol plus Folic Acid versus Combined Oral Treatment on Androgen Levels in PCOS Women
    • 10
    • Highly Influenced
    • PDF
    Effects of ethinyl estradiol-cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome
    • 12
    Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome
    • F. Karakurt, I. Gumus, +6 authors A. Akçay
    • Medicine
    • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
    • 2008
    • 23